YWO NEWS | EQUITIES | DEEP DIVE / ANALYSIS
AstraZeneca’s London-listed shares fell 9.1% on Thursday — the worst single-session drop since March 2020 — after the British drugmaker announced that its late-stage heart disease trial for Wainua failed to meet its primary endpoint, CNBC’s Elsa Ohlen reported. NYSE-listed AZN shares were down 8.4% in premarket trading.
The drug, Wainua, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy — ATTR-CM — a rare, life-threatening condition in which misfolded proteins accumulate in the heart muscle, stiffening it and ultimately leading to heart failure. Over 140 weeks, Wainua added on top of standard care did not show a statistically meaningful reduction in deaths and recurrent heart-related emergencies compared to placebo, AstraZeneca confirmed in a press release Thursday morning. Roughly half a million people live with the condition globally.
Trial Results and Patient Cohort Considerations
According to AstraZeneca and analysts cited by CNBC, attention has focused on aspects of the study design when assessing the trial outcome. In the study cohort, 57% of patients were already receiving a stabilizer treatment at baseline — a drug that prevents the protein from misfolding in the first place. A further 24% initiated a stabilizer during the trial. According to the reported trial results, Wainua did not demonstrate a statistically significant improvement in the primary endpoint when added to standard care.
For patients who had not taken a stabilizer at baseline, Wainua did show a “nominally significant” risk reduction in deaths and heart events versus placebo, AstraZeneca said. Although the subgroup findings did not alter the primary endpoint, AstraZeneca reported them as part of the overall study results. .
Jefferies analysts, cited by CNBC, were direct about the reputational dimension:
“AstraZeneca is meant to be able to have ‘exceptionally good trial design ability,’ and to see the trial fail on design flaws like the percentage of patients on stabilizers, will hit the company’s credibility.”
Jefferies attributed significance to the study design when discussing the trial outcome. . Over 14 years as CEO, AstraZeneca built its standing partly on the premise that it ran tight trials, especially in oncology. A failure attributed to patient-cohort design hands critics a structural argument, not just a statistical one.
The $80 Billion Target – Analyst Views Following the Trial Results
Jefferies did not move to jeopardise AstraZeneca’s $80 billion sales target by 2030, but modelled for $2.5 billion less in risk-adjusted sales for Wainua specifically, CNBC reported. The analysts flagged that AstraZeneca “had been very confident around the primary endpoint and the ability to hit in combination use” — which makes the miss harder to absorb than a trial where management had already flagged uncertainty.
“The bigger issue is probably a degree of credibility loss with management being very confident in the trial’s ability to hit the primary endpoint as well as an ability to show utility on top of background therapy,” Jefferies said.
Citi, also cited by CNBC, went further on the commercial path: it said it was unlikely AstraZeneca could file for additional ATTR-CM approvals for Wainua given the primary endpoint miss, pointing to Alnylam Pharmaceuticals’ existing approved treatment for the same indication as the competitive barrier.
AstraZeneca confirmed that Wainua’s existing licence was unaffected. The drug is already approved for conditions where misfolded proteins cause nerve damage rather than cardiac damage, and is sold in Europe under the brand name Wainzua. Thursday’s failure applies specifically to the cardiac-use expansion, not the underlying approval.
Co-Developer Ionis and Competitor Alnylam Move in Opposite Directions
The collateral damage ran directly to Ionis Pharmaceuticals, which is co-developing Wainua in the United States. IONS shares fell 20% in premarket trading Thursday, CNBC reported — a move roughly twice as severe as AstraZeneca’s own decline, reflecting the drug’s proportionally larger importance to Ionis’s pipeline.
In contrast, Alnylam Pharmaceuticals shares rose 17% in premarket trading on the same news. Alnylam already has a treatment for ATTR-CM on the market, and the Wainua failure removes a competing therapy before it could challenge that position. The three-way split — AZN down 9%, IONS down 20%, ALNY up 17% — reflecting differing market reactions following the announcement.
What Comes After This
Jefferies noted that the stock may not recover its footing until AstraZeneca’s next major catalyst — the AVANZAR trial for cancer — delivers a result, CNBC reported. The analysts said they “would not be surprised seeing people pause for now until the catalyst path is clearer.” That framing positions the current dislocation as a holding pattern, not necessarily a structural re-rating — though the credibility question Jefferies raised may take more than one clean readout to fully address.
AstraZeneca has not announced a revised timeline or filing plan for Wainua in the cardiac indication following Thursday’s announcement. The company’s press release confirmed only that the existing licence remains intact and that it believes the results “support greater scientific” understanding — a phrase that was cut off in the available source text, CNBC noted the full statement was published Thursday morning.
| Asset | Move | Context |
|---|---|---|
| AZN (London) | −9.1% | Worst day since March 2020 |
| AZN (NYSE, premarket) | −8.4% | Per CNBC premarket data |
| IONS (premarket) | −20% | Co-developer of Wainua |
| ALNY (premarket) | +17% | Competitor with existing ATTR-CM drug on market |
Sources: CNBC
Jefferies noted that it continues to model AstraZeneca’s broader long-term revenue target despite reducing its risk-adjusted sales estimate for Wainua. The analysts also highlighted management credibility as a factor they believe market participants may continue to monitor following the trial results.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument.